Skip to main content

Together we are beating cancer

Donate now

Cancer type

Showing 12 out of 2908 results

It’s completely up to you whether to go to cervical cancer screening. But the answers to these 6 questions could help you decide. It’s completely up to you whether to go to cervical cancer screening. But the answers to these 6 questions could help you decide.

by Rachel Orritt | Analysis | 25 October 2021

25 October 2021

Barrett's oesophagus under the microscope

Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now. Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now.

by Harry Jenkins | Analysis | 25 October 2021

25 October 2021

prostate cancer biopsy
  • Science & Technology
  • Health & Medicine

Targeted prostate cancer screening: Are we there yet?

Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet? Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet?

by Katie Roberts | Analysis | 20 October 2021

20 October 2021

3D representation of oesophageal cancer

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

by Harry Jenkins | News | 20 October 2021

20 October 2021

That Cancer Conversation in a white speech bubble with a dark blue background

From groundbreaking rare cancer research to ending up on Forbes 30 under 30, we chat to Sigourney Bell about her work in the lab and her global organisation, Black in Cancer. From groundbreaking rare cancer research to ending up on Forbes 30 under 30, we chat to Sigourney Bell about her work in the lab and her global organisation, Black in Cancer.

by Cancer Research UK | Podcast | 8 October 2021

8 October 2021

This entry is part 3 of 37 in the series That Cancer Conversation
%postcontent%
  • For Researchers
  • Science & Technology

Delivering the future of paediatric brain tumour therapy

Dr Lisa Ruff tells us why drug delivery is so important for the treatment of paediatric brain tumours – and why hydrogels could be key to a breakthrough… Dr Lisa Ruff tells us why drug delivery is so important for the treatment of paediatric brain tumours – and why hydrogels could be key to a breakthrough…

by Phil Prime | Research Feature | 7 October 2021

7 October 2021

3D visualisation of thyroid cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer. The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

by Harry Jenkins | News | 1 October 2021

1 October 2021

Amarvir (pictured with his dad Jag) was diagnosed with acute lymphoblastic leukaemia in 2010.

Since the 1970s, 30,000 deaths have been avoided thanks in part to the progress we’ve made in diagnosing and treating children's and young people's cancers. Since the 1970s, 30,000 deaths have been avoided thanks in part to the progress we’ve made in diagnosing and treating children's and young people's cancers.

by Harry Jenkins | Analysis | 29 September 2021

29 September 2021